Abstract: IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

Abstract: IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

Abstract: The present invention relates to N-containing fused heterocyclic compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen, halogen, aryl, lower alkyl, halo (lower) alkyl or nitro,R.sub.3 is lower alkylene,R.sub.4 and R.sub.5 are each lower alkylene,X is CH or N,Y is S, O, NH, C.dbd.N--OH or CO,Z is O or NH, andA is hydrogen, nitroso, amidino, a group of ##STR2## wherein R.sub.6 and R.sub.7 are each hydrogen, lower alkyl, acyl, or lower alkaneimidoyl which may be substituted with esterified carboxy, or a group of the formula:--N.dbd.R.sub.8,wherein R.sub.8 is lower alkylidene which may be substituted with aryl optionally substituted with suitable substituent(s).The compounds are useful for treatment of thrombosis, inflammation, or allergic disease.

Abstract: The present invention relates to imidazopyridine compounds of the formula: ##STR1## wherein R.sup.1 is lower alkynyl or lower alkynyloxy(lower)-alkyl,R.sup.2 is lower alkyl, andR.sup.3 is ar(lower)alkyl having lower alkoxy, lower alkylthio, nitro or lower alkanesulfonyl, ar(lower)alkyl having nitro and one or two additional substituent(s) selected from nitro and lower alkyl, or heterocyclic(lower)alkyl which may have suitable substituent(s), and to their utility.The compounds have antiulcerative properties.

Abstract: This invention provides a benezene-fused heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is halogen, nitro, amino, hydroxy, lower alkyl, lower alkoxy substituted by carboxy or protected carboxy, acylamino which may have lower alkyl on the amino moiety, or aryloxy which may have halogen,R.sup.2 is hydrogen or halogen,X is --O-- or ##STR2## in which R.sup.3 is hydrogen, lower alkyl or acyl and A is a group of the formula: ##STR3## in which R.sup.4 is hydrogen, lower, alkenyl, lower alkynyl or alkyl which may have suitable substituent(s) selected from the groups consisting of hydroxy, acyl, lower alkoxy, di(lower)alkylamino, carboxy, protected carboxy and aryl; orR.sup.1 is hydrogen or lower alkoxy,R.sup.2 is hydrogen,X is ##STR4## in which R.sub.a.sup.3 is lower alkanoyl and A is a group of the formula: ##STR5## and pharmaceutically acceptable salts thereof.

Abstract: This invention provides a oxothiazolidine compound of the formula: ##STR1## wherein R.sup.1 is acyl;di(lower)alkylamino(lower)alkylcarbamoyl(lower)alkyl; arylcarbamoyl(lower)alkyl;ar(lower)alkylcarbamoyl(lower)alkyl;heterocyclic carbamoyl(lower)alkyl;heterocyclic(lower)alkylcarbamoyl(lower)alkyl;thiazolidinylcarbonyl(lower)alkyl;morpholinylcarbonyl(lower)alkyl or a group of the formula: ##STR2## in which A is lower alkylene;n is an integer of 0 or 1;m is an integer of 2 or 3;X is --N--, ##STR3## or --CH-- and R.sup.2 is hydroxy;lower alkyl which may have hydroxy;ar(lower)alkyl which may have halogen;arylthio which may have halogen;acyl or heterocyclic group andY is --S--, ##STR4## or pharmaceutically acceptable salt thereof. This compound is useful as cognition activator. This invention further provides processes for the preparation of this compound and pharmaceutical composition comprising compound of the above formula.

Abstract: The present invention relates to a .sup.59 Valine insulin-like growth factor I (.sup.59 Val.IGF-I), to a .sup.59 Val-IGF-I fused to a protective peptide, to a gene coding for .sup.59 Val-IGF-I, to a gene coding for fused .sup.59 Val-IGF-I, to a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the fused .sup.59 Val-IGF-I gene, and to processes for the production of these.

Abstract: A thiazole compound of allergically activity of the formula: ##STR1## wherein R.sup.1 is amino optionally having suitable substituent(s),R.sup.2 is hydrogen, lower alkyl or aryl,R.sup.3 is hydrogen, nitro, amino optionally having suitable substituent(s), hydroxy or lower alkoxy,A is lower alkylene,Q is hydrogen or halogen, anda heavy solid line means a single or double bond,or a pharmaceutically acceptable salt thereof, processes for the preparation thereof and pharmaceutical composition comprising the same.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl,R.sup.3 is hydrogen, halogen or ar(lower)alkoxy, andR is lower alkanoyl, nitroso, amino, carboxy, esterified carboxy, carbamoyl, hydroxycarbamoyl, haloformyl, aminomethyleneamino which may be substituted with cyano or lower alkyl, iminomethylamino which may be substituted with cyano or lower alkyl, or a group of the formula: --A--R.sup.2 in which A is lower alkylene andR.sup.2 is di(lower) alkylamino, cyano, lower alkoxy, N-containing heterocyclic group which may have suitable substituent(s), lower alkynyloxy, lower alkenyloxy, lower alkylthio, amino(lower)alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, carboxy, esterified carboxy, carbamoyl, hydroxycarbamoyl, hydroxy, lower alkanoyloxy, heterocyclicamino(lower)alkylthio having two oxo groups, hydrogen or a group of the formula: ##STR2## in which R.sup.4, R.sup.5 and R.sup.6 are each lower alkyl andX is an acid residue,and pharmaceutically acceptable salts thereof.

Abstract: This invention provides a piperidine compound of the formula: ##STR1## wherein R.sup.1 is hydrogen or trihalomethyl,R.sup.2 is hydrogen or protected carboxy,R.sup.3 is heterocyclic group or aryl which may be halogen substituted, andX is --S--, ##STR2## --O--, --NH-- or lower alkylene which may be hydroxy substituted, and pharmaceutically acceptable salt thereof, These compounds possess hypotensive activity and are useful as anti-hypertensive agents. The invention further relates to processes for the preparation of these compounds and pharmaceutical compositions comprising compounds of the above formula.

Abstract: The invention relates to novel cephem compounds of high antimicrobial activity of the formula: ##STR1## wherein R.sup.1 is amino or protected amino,R.sup.2 is halogen,R.sup.3 is hydrogen or lower alkyl,R.sup.4 is hydrogen, lower alkyl or lower alkoxy,R.sup.5 is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxymethyl or unsaturated heterocyclicthiomethyl in which the heterocyclic moiety may be substituted with lower alkyl or lower alkenyl, andR.sup.6 is carboxy or functionally modified carboxy, and its pharmaceutically acceptable salt thereof.

Abstract: Certain imidazo[1,2-a]heterocyclic compounds useful in the treatment of ulcers are provided.

Abstract: Anti-allergic quinazolinone derivatives are disclosed which have the formula ##STR1## wherein R.sup.3 is hydrogen or lower alkyl and A is lower alkylene.

Abstract: This invention concerns antibiotic cephalosporins of the formula ##STR1## wherein R.sup.1 is amino or protected amino; R.sup.2 is halogen; R.sup.3 is alkyl; and R.sup.6 is carboxy or protected carboxy.

Abstract: This invention provides a benzene-fused heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is halogen, nitro, amino, hydroxy, lower alkyl, lower alkoxy or acylamino,X is --S--, ##STR2## n is an integer of 1 or 2 and A is a group of the formula: ##STR3## in which R.sup.2 is hydrogen, lower alkyl, lower alkynyl, carboxy(lower)alkyl or protected carboxy(lower)alkyl, or pharmaceutically acceptable salts thereof. This compound possesses diuretic, uricosuric, and vasodilative activities and therefore is useful as a diuretic agent, uricosuric agent and anti-hypertensive agent. This invention further provides processes for the preparation of this compound and pharmaceutical composition comprising compound of the above formula.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl,R.sup.3 is hydrogen, halogen or ar(lower)alkoxy, andR is lower alkanoyl, nitroso, amino, carboxy, esterified carboxy, carbamoyl, hydroxycarbamoyl, haloformyl, aminomethyleneamino which may be substituted with cyano or lower alkyl, iminomethylamino which may be substituted with cyano or lower alkyl, or a group of the formula: --A--R.sup.2 in whichA is lower alkylene andR.sup.2 is di(lower)alkylamino, cyano, lower alkoxy, N-containing heterocyclic group which may have suitable substituent(s), lower alkynyloxy, lower alkenyloxy, lower alkylthio, amino(lower)alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, carboxy, esterified carboxy, carbamoyl, hydroxycarbamoyl, hydroxy, lower alkanoyloxy, heterocyclicamino (lower)alkylthio having two oxo groups, hydrogen or a group of the formula: ##STR2## in which R.sup.4, R.sup.5 and R.sup.6 are each lower alkyl andX is an acid residue,and pharmaceutically acceptable salts thereof.

Abstract: This invention provides a benezene-fused heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is halogen, nitro, amino, hydroxy, lower alkyl, lower alkoxy substituted by carboxy or protected carboxy, acylamino which may have lower alkyl on the amino moiety, or aryloxy which may have halogen,R.sup.2 is hydrogen or halogen,X is --O-- or ##STR2## in which R.sup.3 is hydrogen, lower alkyl or acyl and A is a group of the formula: ##STR3## in which R.sup.4 is hydrogen, lower alkenyl, lower alkynyl or alkyl which may have suitable substituent(s) selected from the groups consisting of hydroxy, acyl, lower alkoxy, di(lower)alkylamino, carboxy, protected carboxy and aryl; orR.sup.1 is hydrogen or lower alkoxy,R.sup.2 is hydrogen,X is ##STR4## in which R.sub.a.sup.3 is lower alkanoyl and A is a group of the formula: ##STR5## and pharmaceutically acceptable salts thereof.

Abstract: Pyrimidoisoquinoline/compounds of the formula: ##STR1## where R.sup.1 is H, halogen or lower alkyl, R.sup.2 is NH.sub.2, NO.sub.2 or acylamino and R.sup.3 is carboxy or protected carboxy, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof are disclosed in this application. Also disclosed is a method of treating allergies by administering the compounds of this invention.

Abstract: Compounds of the formula ##STR1## are disclosed whereinR.sup.1 is hydrogen or lower alkyl, one of R.sup.2 and R.sup.3 is mono (or di)-nitroxy(lower)alkyl and the otherR.sup.2 and R.sup.3 is hydrogen and pharmaceutically acceptable salts thereof.Also disclosed are vasodilating compositions containing the above.

Abstract: The present invention relates to novel quinazolinone derivatives and pharmaceutically acceptable salts thereof. More particularly, it relates to novel quinazolinone derivatives and pharmaceutically acceptable salts thereof which have antiallergic activities, to processes for the preparation thereof, to pharmaceutical composition comprising the same, and to a method of using the same therapeutically in the treatment of allergic symptoms in human being and animals.